lumistobart (BR105) / BioRay Biopharmaceutical - LARVOL DELTA

Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval (PRNewswire) - "BioRay Pharmaceutical Co., Ltd...announced on October 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration (FDA). This marks BioRay's first project to receive FDA IND approval....Phase I clinical trial of BR105 Injection is currently on-going in China, and preliminary result has confirmed its good clinical safety."

IND • Trial status • Oncology • Solid Tumor

BR105-I: Phase I Clinical Study of BR105 Injection (clinicaltrials.gov) - P1 | N=162 | Not yet recruiting | Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

New P1 trial • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Solid Tumor